Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.

Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Isotretinoin shows promise as a treatment for Chagas disease by effectively inhibiting key transporters in the parasite.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

A CCS patient with severe complications was successfully treated using combined therapies.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

HIV medication ritonavir can increase the effects of nasal sprays like fluticasone, causing Cushing's syndrome.

CTHRC1 helps sweat glands recover by rebuilding nearby blood vessels.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Adding a second method to PROTACs could improve cancer treatment.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.

Targeting NETs may help reduce fibrosis in Crohn's disease.

Recombinant thymosin β4 promotes blood vessel growth and reduces muscle damage.

The new assay can help develop products for hair re-growth.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

Apraglutide and N-acetylcysteine (NAC) show promise in reducing cytarabine's harmful effects on organs.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.